EyePoint Pharmaceuticals, Inc. (EYPT)

Market Cap	431.48M
Revenue (ttm)	45.71M
Net Income (ttm)	-103.57M
Shares Out	70.16M
EPS (ttm)	-2.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	603,657
Open	6.48
Previous Close	6.35
Day's Range	6.09 - 6.55
52-Week Range	5.90 - 29.31
Beta	1.52
Analysts	Strong Buy
Price Target	25.71 (+318.05%)
Earnings Date	Mar 6, 2025

About EYPT

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 27, 2005
• Employees: 121
• Stock Exchange: NASDAQ
• Ticker Symbol: EYPT
• Website: https://eyepointpharma.com

Financial Performance

In 2023, EyePoint Pharmaceuticals's revenue was $46.02 million, an increase of 11.14% compared to the previous year's $41.40 million. Losses were -$70.80 million, -30.77% less than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for EYPT stock is "Strong Buy." The 12-month stock price forecast is $25.71, which is an increase of 318.05% from the latest price.

Price Target

$25.71

(318.05% upside)

Analyst Consensus: Strong Buy